Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
Get Alerts SRPT Hot Sheet
Rating Summary:
30 Buy, 9 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Needham & Company analyst Chad Messer reiterated a Buy rating and $55 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain confident in Eteplirsen approval following Drisapersen's AdCom.
Messer commented, "As expected, most of the discussion yesterday was around inconsistencies in the drisapersen dataset as well as safety concerns. However, we do not necessarily believe the Advisory Committee (AdComm) would have voted against approval. We point out that the FDA did not include a customary yes/no approval voting question on the agenda. Regardless of the fate of drisapersen, we do not believe eteplirsen suffers from the same issues, as we wrote last week (11/20). We additionally point out that Sarepta endured multiple delays in the eteplirsen NDA filing as it sought to cooperate with FDA requests. We do not believe the same level of cooperation exists between FDA and Biomarin."
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $37.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walt Disney (DIS) PT Raised to $145 at Needham
- Mereo BipPharma Group (MREO) PT Raised to $6 at Needham on increased 'launch expectations for setrusumab in OI'
- Dollar General (DG) PT Raised to $175 at Argus
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!